Bird Rock Bio: Bird Rock Bio files IND application for phase 2 study of Nimacimab for treatment of renal diseases

Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 (CB1) receptor, which has a known association in renal fibrosis and inflammation. Bird Rock Bio owns the worldwideThe post Bird Rock Bio files IND application for phase 2 study of Nimacimab for treatment of renal diseases appeared first on Pharmaceutical Business review.